119 related articles for article (PubMed ID: 36121194)
1. CRISPR/Cas9-HPV-liposome enhances antitumor immunity and treatment of HPV infection-associated cervical cancer.
Zhen S; Qiang R; Lu J; Tuo X; Yang X; Li X
J Med Virol; 2023 Jan; 95(1):e28144. PubMed ID: 36121194
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.
Zhen S; Lu J; Liu YH; Chen W; Li X
Cancer Gene Ther; 2020 Apr; 27(3-4):168-178. PubMed ID: 31455836
[TBL] [Abstract][Full Text] [Related]
3. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
[TBL] [Abstract][Full Text] [Related]
5. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer.
Ling K; Yang L; Yang N; Chen M; Wang Y; Liang S; Li Y; Jiang L; Yan P; Liang Z
Hum Gene Ther; 2020 Mar; 31(5-6):297-308. PubMed ID: 31989837
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease.
Kennedy EM; Kornepati AV; Goldstein M; Bogerd HP; Poling BC; Whisnant AW; Kastan MB; Cullen BR
J Virol; 2014 Oct; 88(20):11965-72. PubMed ID: 25100830
[TBL] [Abstract][Full Text] [Related]
7. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m
Hu C; Liu T; Han C; Xuan Y; Jiang D; Sun Y; Zhang X; Zhang W; Xu Y; Liu Y; Pan J; Wang J; Fan J; Che Y; Huang Y; Zhang J; Ding J; Yang S; Yang K
Int J Biol Sci; 2022; 18(2):507-521. PubMed ID: 35002506
[TBL] [Abstract][Full Text] [Related]
8. TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy.
Hu Z; Ding W; Zhu D; Yu L; Jiang X; Wang X; Zhang C; Wang L; Ji T; Liu D; He D; Xia X; Zhu T; Wei J; Wu P; Wang C; Xi L; Gao Q; Chen G; Liu R; Li K; Li S; Wang S; Zhou J; Ma D; Wang H
J Clin Invest; 2015 Jan; 125(1):425-36. PubMed ID: 25500889
[TBL] [Abstract][Full Text] [Related]
9. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
10. Genome editing mRNA nanotherapies inhibit cervical cancer progression and regulate the immunosuppressive microenvironment for adoptive T-cell therapy.
Ling K; Dou Y; Yang N; Deng L; Wang Y; Li Y; Yang L; Chen C; Jiang L; Deng Q; Li C; Liang Z; Zhang J
J Control Release; 2023 Aug; 360():496-513. PubMed ID: 37423524
[TBL] [Abstract][Full Text] [Related]
11. Systemic Delivery of CRISPR/Cas9 Targeting HPV Oncogenes Is Effective at Eliminating Established Tumors.
Jubair L; Fallaha S; McMillan NAJ
Mol Ther; 2019 Dec; 27(12):2091-2099. PubMed ID: 31537455
[TBL] [Abstract][Full Text] [Related]
12. The application of CRISPR/Cas9 system in cervical carcinogenesis.
Gao C; Wu P; Yu L; Liu L; Liu H; Tan X; Wang L; Huang X; Wang H
Cancer Gene Ther; 2022 May; 29(5):466-474. PubMed ID: 34349239
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness.
Leung TH; Tang HW; Siu MK; Chan DW; Chan KK; Cheung AN; Ngan HY
J Pathol; 2018 Feb; 244(2):151-163. PubMed ID: 28944962
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes.
Nishida H; Matsumoto Y; Kawana K; Christie RJ; Naito M; Kim BS; Toh K; Min HS; Yi Y; Matsumoto Y; Kim HJ; Miyata K; Taguchi A; Tomio K; Yamashita A; Inoue T; Nakamura H; Fujimoto A; Sato M; Yoshida M; Adachi K; Arimoto T; Wada-Hiraike O; Oda K; Nagamatsu T; Nishiyama N; Kataoka K; Osuga Y; Fujii T
J Control Release; 2016 Jun; 231():29-37. PubMed ID: 26979870
[TBL] [Abstract][Full Text] [Related]
15. Hyperbranched poly(β-amino ester) based polyplex nanopaticles for delivery of CRISPR/Cas9 system and treatment of HPV infection associated cervical cancer.
Gao X; Jin Z; Tan X; Zhang C; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; He D; Ma X; Tian X; Gao Q; Wu J; Tian R; Cui Z; Fan W; Huang Z; Cao C; Bao Y; Tan S; Hu Z
J Control Release; 2020 May; 321():654-668. PubMed ID: 32114092
[TBL] [Abstract][Full Text] [Related]
16. Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
Sato N; Saga Y; Uchibori R; Tsukahara T; Urabe M; Kume A; Fujiwara H; Suzuki M; Ozawa K; Mizukami H
Int J Oncol; 2018 Mar; 52(3):687-696. PubMed ID: 29344635
[TBL] [Abstract][Full Text] [Related]
17. HPV-16 E6/E7 promotes cell migration and invasion in cervical cancer via regulating cadherin switch in vitro and in vivo.
Hu D; Zhou J; Wang F; Shi H; Li Y; Li B
Arch Gynecol Obstet; 2015 Dec; 292(6):1345-54. PubMed ID: 26093522
[TBL] [Abstract][Full Text] [Related]
18. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
20. KSHV co-infection down-regulates HPV16 E6 and E7 from cervical cancer cells.
Dai L; Cao Y; Jiang W; Zabaleta J; Liu Z; Qiao J; Qin Z
Oncotarget; 2017 May; 8(22):35792-35803. PubMed ID: 28415759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
